leadf
logo-loader
viewRevive Therapeutics

Revive Therapeutics in research collaboration to develop psilocybin to treat cancer and discover novel uses of undisclosed psychedelic compounds

Revive will advance the development of PharmaTher’s recent discovery in the potential of psilocybin to treat certain cancers of the liver and kidneys, among others

Revive Therapeutics - Revive Therapeutics Ltd enters into research collaboration with PharmaTher Inc to develop psilocybin to treat cancer and discover novel uses of undisclosed psychedelic compounds
Revive will leverage PharmaTher’s panaceAI discovery artificial intelligence platform to discover new uses of undisclosed psychedelic compounds

Revive Therapeutics Ltd (CSE:RVV) (OTCMKTS:RVVTF) (FRA:31R) has entered into an exclusive research collaboration agreement with PharmaTher Inc to accelerate the development of psilocybin to treat cancer and the discovery of novel uses of undisclosed psychedelic compounds. 

PharmaTher is a wholly-owned subsidiary of Newscope Capital Corporation (CSE:PHRM), a specialty psychedelics pharmaceutical company. 

"Revive continues to be focused on developing novel uses for psilocybin that leverages our proprietary oral thin film delivery technology as a differentiated therapeutic approach," said Revive CEO Michael Frank in a statement Wednesday. "We are excited to advance the development of PharmaTher’s recent discovery in the potential of psilocybin to treat certain cancers such as liver carcinoma, melanoma, breast neoplasms, kidney neoplasms and acute myeloid leukemia."

READ: Revive Therapeutics commits to 10 sites for Phase 3 coronavirus trial of bucillamine

Frank added: “We are also leveraging PharmaTher’s panaceAI discovery AI platform to discover new uses of undisclosed psychedelic compounds to be potentially used with our oral thin film delivery technology and expand our psychedelics drug pipeline."

Fabio Chianelli, CEO of PharmaTher, noted that his company achieved an important milestone in expanding its patent portfolio with the potential of psilocybin to treat certain cancer indications. 

“Our research collaboration with Revive validates our business model in discovering novel uses of psychedelics with panaceAI and partnering these discoveries with life sciences companies seeking to expand their product pipeline with psychedelics,” Chianelli said. “We are happy to accelerate Revive’s objective in building a unique psychedelic drug pipeline via the FDA development and approval process.”

Revive said the collaboration will give it exclusivity to advance the research of psilocybin in the treatment of cancer and leverage PharmaTher’s panaceAI psychedelic discovery AI (artificial intelligence) platform to screen, identify and evaluate undisclosed psychedelic compounds directed at pre-specified targets for use with Revive’s drug delivery technology.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Revive Therapeutics

Price: 0.275 CAD

CSE:RVV
Market: CSE
Market Cap: $54.97 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Revive Therapeutics named herein, including the promotion by the Company of Revive Therapeutics in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Revive Therapeutics: Analyst sees 'substantial upside potential' as key...

Proactive Research analyst Ed Stacey says Revive Therapeutics (CSE:RVV)(OTCQB:RVVTF) is a speciality life sciences company focussed on repurposing drugs for rare and infectious diseases and has a pipeline of of three main platforms. One of them is Bucillamine (BUC) which is a medication with a...

on 06/30/2020

2 min read